Allergy Therapeutics plc Extends Anapen(C) Distribution Agreement into UK and Ireland
Anapen®, produced by Lincoln Medical Limited, is indicated for the treatment of anaphylactic shock. Anaphylactic shock is a life threatening allergic reaction with increasing prevalence in all developed countries. Anapen® is the only epinephrine pen auto injector in the world with a 500 micrograms presentation. The 500 microgram presentation is indicated for people weighing above 65kg, giving Anapen® a strong competitive advantage.
The epinephrine pen auto injector market in the UK is valued at around £20 million and grew by 20% last year. Anapen® is already launched in the UK and Ireland and Allergy Therapeutics expects sales of up to £2 million in those countries during the next 12 months. Anapen® will be an important new product for Allergy’s UK sales force and is targeted at similar physicians to those prescribing the Company’s lead product Pollinex Quattro for the treatment of allergic conditions.
Allergy Therapeutics has been selling Anapen® in The Netherlands since September 2010 and has also received the exclusive rights to distribute Anapen® in Italy, Spain, Belgium, Poland, Argentina, Venezuela, Colombia and Chile, all countries with promising market potential. The Company expects to launch Anapen® in these countries during the next 12 months, subject to regulatory approvals.
For further information
Allergy Therapeutics +44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Nomura Code Securities - NOMAD +44 (0) 207 776 1200
Juliet Thompson/ Clare Terlouw
Financial Dynamics +44 (0) 207 831 3113
Jonathan Birt/ Susan Quigley
Victoria Foster Mitchell
Consultant
FD Santé
Holborn Gate, 26 Southampton Buildings
London, WC2A 1PB
D +44 (0)20 3077 0486
M +44 (0)7816 944 230
www.fd.com